Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2023-11-29 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
2023年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions passed at the 2023 fourth extraordinary general meeting of shareholders of Dongbei Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, only the official voting results and meeting details. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2023-11-29 Chinese
北京德恒律师事务所关于东北制药集团股份有限公司2023年第四次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality and procedural compliance of the company's 2023 fourth extraordinary general meeting (临时股东大会). It details the meeting's convening, attendance, voting procedures, and results. The document does not contain financial statements or performance data but focuses on the legal validation of the shareholder meeting process and voting outcomes. It is not an announcement of voting results per se but a legal opinion on the meeting's conduct and resolutions. Given the nature of the document as a legal opinion on a shareholder meeting, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document length is 4522 characters, which is sufficient to be the actual legal opinion rather than a brief announcement or report publication notice.
2023-11-29 Chinese
关于召开公司2023年第四次临时股东大会的提示性公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement about the convening of the company's 2023 fourth extraordinary general meeting of shareholders, including meeting details, voting procedures, and proxy forms. It does not contain financial statements or results but rather logistical and procedural information about the shareholder meeting and voting. It is not a report itself but an announcement related to a shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is primarily a notice about the meeting and voting procedures rather than solicitation materials, the best fit is DVA, which covers official results and voting rights announcements. The document length is under 5,000 characters and is a notice rather than a full report, so it is not an Annual Report or Interim Report. Hence, the classification is DVA with high confidence.
2023-11-23 Chinese
关于职工监事变动的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding a change in the company's supervisory board personnel, specifically the resignation of a staff supervisor and the election of a new one. It includes details about the new supervisor's qualifications and compliance with regulatory requirements. There is no financial data, report, or presentation content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2023-11-21 Chinese
关于2022年限制性股票激励计划预留授予部分第一个解除限售期解除限售股份上市流通的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company about the first unlocking period of restricted stock under its 2022 restricted stock incentive plan. It includes information about the approval process, conditions for lifting restrictions, number of shares involved, board and supervisory committee opinions, legal opinions, and the schedule for shares to become tradable. The document is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is a regulatory announcement related to stock incentive plan implementation and share unlocking. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about share unlocking and stock incentive plan progress, which fits best under Regulatory Filings (RNS). The document length (8411 characters) and detailed content confirm it is not a brief announcement or a report publication announcement (RPA). Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-11-16 Chinese
独立董事对公司第九届董事会第二十二次会议相关议案发表的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on specific board meeting proposals related to the company's 2022 restricted stock incentive plan, including approval of lifting restrictions on stock and a proposed repurchase and cancellation of certain restricted stocks. It references compliance with stock exchange listing rules and company articles but does not contain financial statements or detailed financial data. The document is a formal opinion related to board decisions rather than a full report or announcement of voting results. It is not a full Annual Report, Interim Report, or Earnings Release. It is also not a simple announcement or certification. The content fits best under Board/Management Information (MANG) as it relates to board meeting matters and management decisions on stock incentive plans.
2023-11-13 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.